{"id": "article-18172_0", "title": "Bacillus Calmette Guerin -- Continuing Education Activity", "content": "Bacillus Calmette-Guerin (BCG) is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. The vaccine was developed by Calmette and Guerin and was first administered to human beings in 1921. BCG is the only vaccine against tuberculosis. It is the most widely administered vaccine and usually a part of the routine newborn immunization schedule. BCG vaccine also offers protection against non-tuberculous mycobacterial infections like leprosy and Buruli ulcer. This activity reviews the mode of action of the BCG vaccine and highlights the role of the interprofessional team in educating patients about tuberculosis prevention.", "contents": "Bacillus Calmette Guerin -- Continuing Education Activity. Bacillus Calmette-Guerin (BCG) is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. The vaccine was developed by Calmette and Guerin and was first administered to human beings in 1921. BCG is the only vaccine against tuberculosis. It is the most widely administered vaccine and usually a part of the routine newborn immunization schedule. BCG vaccine also offers protection against non-tuberculous mycobacterial infections like leprosy and Buruli ulcer. This activity reviews the mode of action of the BCG vaccine and highlights the role of the interprofessional team in educating patients about tuberculosis prevention."}
{"id": "article-18172_1", "title": "Bacillus Calmette Guerin -- Continuing Education Activity", "content": "Objectives: Describe the mode of action of the BCG vaccine. Review the indications for the BCG vaccine. Summarize the clinical relevance of the BCG vaccine. Outline the importance of improving care coordination among interprofessional team members to improve outcomes in patients receiving the BCG vaccine. Access free multiple choice questions on this topic.", "contents": "Bacillus Calmette Guerin -- Continuing Education Activity. Objectives: Describe the mode of action of the BCG vaccine. Review the indications for the BCG vaccine. Summarize the clinical relevance of the BCG vaccine. Outline the importance of improving care coordination among interprofessional team members to improve outcomes in patients receiving the BCG vaccine. Access free multiple choice questions on this topic."}
{"id": "article-18172_2", "title": "Bacillus Calmette Guerin -- Introduction", "content": "Bacillus Calmette-Gu\u00e9rin (BCG) is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. The vaccine was developed by Calmette and Gu\u00e9rin and was first administered to human beings in 1921. BCG is the only vaccine against tuberculosis. It is the most widely administered vaccine and usually a part of the routine newborn immunization schedule.\u00a0 BCG vaccine also offers protection against non-tuberculous mycobacterial infections\u00a0like\u00a0leprosy and Buruli ulcer. It is also used in the treatment of superficial carcinoma of the bladder.", "contents": "Bacillus Calmette Guerin -- Introduction. Bacillus Calmette-Gu\u00e9rin (BCG) is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. The vaccine was developed by Calmette and Gu\u00e9rin and was first administered to human beings in 1921. BCG is the only vaccine against tuberculosis. It is the most widely administered vaccine and usually a part of the routine newborn immunization schedule.\u00a0 BCG vaccine also offers protection against non-tuberculous mycobacterial infections\u00a0like\u00a0leprosy and Buruli ulcer. It is also used in the treatment of superficial carcinoma of the bladder."}
{"id": "article-18172_3", "title": "Bacillus Calmette Guerin -- Introduction", "content": "BCG vaccine\u00a0is a fairly safe vaccine and\u00a0it is not associated with severe complications. Prior to the mycobacterial infection, vaccine-induced or acquired naturally can protect against subsequent\u00a0infection due to\u00a0mycobacteria including tuberculosis. [1] Prior infection with nontuberculous mycobacteria and Mycobacterium tuberculosis can confer natural protection against tuberculosis infection. [2] [3] Protection against tuberculosis infection is usually due to the immune response to mycobacterial antigens. Prior contained latent infection with Mycobacterium tuberculosis can provide up to\u00a080 percent protection against disease with subsequent exposure. [4] In patients with previous active disease, there is an increased risk of recurrence of active tuberculosis due to distinct strains in both HIV-uninfected and HIV-infected patients. [5] [6] [7] [8] [9] [10] Bacille Calmette-Gu\u00e9rin (BCG) has been associated with a reduction in childhood mortality which is\u00a0not attributable to tuberculosis.\u00a0 Reduction in childhood mortality may be due to epigenetic reprogramming of the nucleotide-binding oligomerization domain (NOD2) receptor. [11] [12] [13] [14]", "contents": "Bacillus Calmette Guerin -- Introduction. BCG vaccine\u00a0is a fairly safe vaccine and\u00a0it is not associated with severe complications. Prior to the mycobacterial infection, vaccine-induced or acquired naturally can protect against subsequent\u00a0infection due to\u00a0mycobacteria including tuberculosis. [1] Prior infection with nontuberculous mycobacteria and Mycobacterium tuberculosis can confer natural protection against tuberculosis infection. [2] [3] Protection against tuberculosis infection is usually due to the immune response to mycobacterial antigens. Prior contained latent infection with Mycobacterium tuberculosis can provide up to\u00a080 percent protection against disease with subsequent exposure. [4] In patients with previous active disease, there is an increased risk of recurrence of active tuberculosis due to distinct strains in both HIV-uninfected and HIV-infected patients. [5] [6] [7] [8] [9] [10] Bacille Calmette-Gu\u00e9rin (BCG) has been associated with a reduction in childhood mortality which is\u00a0not attributable to tuberculosis.\u00a0 Reduction in childhood mortality may be due to epigenetic reprogramming of the nucleotide-binding oligomerization domain (NOD2) receptor. [11] [12] [13] [14]"}
{"id": "article-18172_4", "title": "Bacillus Calmette Guerin -- Introduction", "content": "BCG vaccine can be\u00a0given either intracutaneously or intradermally. Research is currently being conducted on respiratory administration since natural infection, and sensitization to Mycobacterium tuberculosis in humans tend to occur in the respiratory system. [15] [16]", "contents": "Bacillus Calmette Guerin -- Introduction. BCG vaccine can be\u00a0given either intracutaneously or intradermally. Research is currently being conducted on respiratory administration since natural infection, and sensitization to Mycobacterium tuberculosis in humans tend to occur in the respiratory system. [15] [16]"}
{"id": "article-18172_5", "title": "Bacillus Calmette Guerin -- Indications -- Children: Newborns and infants have the greatest benefit from BCG vaccination", "content": "Infants and children \u2264five years with a high risk of exposure to active pulmonary TB. Healthy neonates [17] School-age children (aged 7 to 14) not previously vaccinated. [18] Developed Countries: Consider BCG vaccination in infants and children \u22645 years in the following conditions [19] [20] Prolonged exposure to a patient with untreated, inadequately treated, or isoniazid and rifampin-resistant M. tuberculosis if separation from such exposure is not possible.", "contents": "Bacillus Calmette Guerin -- Indications -- Children: Newborns and infants have the greatest benefit from BCG vaccination. Infants and children \u2264five years with a high risk of exposure to active pulmonary TB. Healthy neonates [17] School-age children (aged 7 to 14) not previously vaccinated. [18] Developed Countries: Consider BCG vaccination in infants and children \u22645 years in the following conditions [19] [20] Prolonged exposure to a patient with untreated, inadequately treated, or isoniazid and rifampin-resistant M. tuberculosis if separation from such exposure is not possible."}
{"id": "article-18172_6", "title": "Bacillus Calmette Guerin -- Indications -- Exposure to MDR-TB", "content": "Consider vaccination in travelers, health care workers, and individuals in the community with exposure to multidrug-resistant (MDR-) tuberculosis. Administer to unvaccinated, tuberculin-negative individuals.", "contents": "Bacillus Calmette Guerin -- Indications -- Exposure to MDR-TB. Consider vaccination in travelers, health care workers, and individuals in the community with exposure to multidrug-resistant (MDR-) tuberculosis. Administer to unvaccinated, tuberculin-negative individuals."}
{"id": "article-18172_7", "title": "Bacillus Calmette Guerin -- Indications -- Health Care Workers", "content": "Routine vaccination of health care workers is not recommended in the United States since infection with tuberculosis is low. BCG vaccine also interferes with the result of a tuberculin skin test that is used to detect Mycobacterium tuberculosis infection. In health care workers, the efficacy of BCG vaccination is not definite. [21] Strict adherence to\u00a0tuberculosis infection control practices should be emphasized in areas with a high incidence of\u00a0disease transmission. Consider BCG vaccination in healthcare workers in regions with high TB transmission Consider vaccination in health care workers from low-risk countries taking care of patients or refugees in TB-endemic countries", "contents": "Bacillus Calmette Guerin -- Indications -- Health Care Workers. Routine vaccination of health care workers is not recommended in the United States since infection with tuberculosis is low. BCG vaccine also interferes with the result of a tuberculin skin test that is used to detect Mycobacterium tuberculosis infection. In health care workers, the efficacy of BCG vaccination is not definite. [21] Strict adherence to\u00a0tuberculosis infection control practices should be emphasized in areas with a high incidence of\u00a0disease transmission. Consider BCG vaccination in healthcare workers in regions with high TB transmission Consider vaccination in health care workers from low-risk countries taking care of patients or refugees in TB-endemic countries"}
{"id": "article-18172_8", "title": "Bacillus Calmette Guerin -- Indications -- Health Care Workers", "content": "BCG immunization guidelines depend on the prevalence of tuberculosis infection. [22] [23] Childhood BCG immunization should be routine in countries with a high prevalence of tuberculosis.\u00a0 In countries with low to intermediate rates of TB (<5/100,000 smear-positive cases per year), BCG immunization should be administered to children at particular risk of TB exposure [23] ( ie children exposed to multidrug-resistant disease).", "contents": "Bacillus Calmette Guerin -- Indications -- Health Care Workers. BCG immunization guidelines depend on the prevalence of tuberculosis infection. [22] [23] Childhood BCG immunization should be routine in countries with a high prevalence of tuberculosis.\u00a0 In countries with low to intermediate rates of TB (<5/100,000 smear-positive cases per year), BCG immunization should be administered to children at particular risk of TB exposure [23] ( ie children exposed to multidrug-resistant disease)."}
{"id": "article-18172_9", "title": "Bacillus Calmette Guerin -- Indications -- Health Care Workers", "content": "BCG vaccination policy is determined by the regional prevalence of tuberculosis infection.\u00a0 Routine neonatal vaccination is recommended by the WHO in countries with moderate to severe prevalence of tuberculosis.\u00a0 Close contacts of patients with TB infection and healthcare workers exposed to patients'\u00a0multidrug-resistant tuberculosis infections with negative tuberculin tests should receive BCG vaccination.\u00a0 Routine BCG vaccination is not recommended in countries with a low prevalence of tuberculosis.\u00a0 Routine BCG vaccination has never been recommended in the United States given the low prevalence of tuberculosis infection.\u00a0 Routine BCG vaccination of children at age 13 and all neonates in high-risk groups was implemented between 1953 and 2005 in the United Kingdom.\u00a0 Routine vaccination was later discontinued in 2005 due to a decreased incidence of tuberculosis infection.", "contents": "Bacillus Calmette Guerin -- Indications -- Health Care Workers. BCG vaccination policy is determined by the regional prevalence of tuberculosis infection.\u00a0 Routine neonatal vaccination is recommended by the WHO in countries with moderate to severe prevalence of tuberculosis.\u00a0 Close contacts of patients with TB infection and healthcare workers exposed to patients'\u00a0multidrug-resistant tuberculosis infections with negative tuberculin tests should receive BCG vaccination.\u00a0 Routine BCG vaccination is not recommended in countries with a low prevalence of tuberculosis.\u00a0 Routine BCG vaccination has never been recommended in the United States given the low prevalence of tuberculosis infection.\u00a0 Routine BCG vaccination of children at age 13 and all neonates in high-risk groups was implemented between 1953 and 2005 in the United Kingdom.\u00a0 Routine vaccination was later discontinued in 2005 due to a decreased incidence of tuberculosis infection."}
{"id": "article-18172_10", "title": "Bacillus Calmette Guerin -- Indications -- Treatment of Bladder Cancer", "content": "A single dose of M. bovis bacillus Calmette-Gu\u00e9rin immunotherapy has a great therapeutic benefit in the treatment of non-invasive forms of bladder cancer. It is administered intravesically and proven benefits include the delay and prevent the progression of the malignancy. [24] [25] [26]", "contents": "Bacillus Calmette Guerin -- Indications -- Treatment of Bladder Cancer. A single dose of M. bovis bacillus Calmette-Gu\u00e9rin immunotherapy has a great therapeutic benefit in the treatment of non-invasive forms of bladder cancer. It is administered intravesically and proven benefits include the delay and prevent the progression of the malignancy. [24] [25] [26]"}
{"id": "article-18172_11", "title": "Bacillus Calmette Guerin -- Contraindications -- Immunocompromised patients", "content": "BCG is a live vaccine and should not be given to: Immunocompromised persons with congenital immunodeficiency, HIV infection, malignancy, or those taking immunosuppressive drugs such as tumor necrosis factor-alpha blockers and corticosteroids Adults with HIV infection living in areas of low TB prevalence", "contents": "Bacillus Calmette Guerin -- Contraindications -- Immunocompromised patients. BCG is a live vaccine and should not be given to: Immunocompromised persons with congenital immunodeficiency, HIV infection, malignancy, or those taking immunosuppressive drugs such as tumor necrosis factor-alpha blockers and corticosteroids Adults with HIV infection living in areas of low TB prevalence"}
{"id": "article-18172_12", "title": "Bacillus Calmette Guerin -- Complications", "content": "Injection site reaction is the most common complication. Injection site reaction includes granulomatous lesions, lymphadenopathy of regional lymph nodes, and nodules or ulcers at the vaccination site with or without draining sinus tracts or fistulae. Mycobacterium bovis is positive when wound culture\u00a0is obtained. One of the adverse effects of BCG is suppurative lymphadenitis, children with primary immunodeficiencies have been shown to have a higher risk of widespread suppurative lymphadenitis and should be avoided. [27] [28] Other complications include: Osteitis Osteomyelitis Disseminated infection may occur in the setting of immunosuppression\u00a0including HIV infection.", "contents": "Bacillus Calmette Guerin -- Complications. Injection site reaction is the most common complication. Injection site reaction includes granulomatous lesions, lymphadenopathy of regional lymph nodes, and nodules or ulcers at the vaccination site with or without draining sinus tracts or fistulae. Mycobacterium bovis is positive when wound culture\u00a0is obtained. One of the adverse effects of BCG is suppurative lymphadenitis, children with primary immunodeficiencies have been shown to have a higher risk of widespread suppurative lymphadenitis and should be avoided. [27] [28] Other complications include: Osteitis Osteomyelitis Disseminated infection may occur in the setting of immunosuppression\u00a0including HIV infection."}
{"id": "article-18172_13", "title": "Bacillus Calmette Guerin -- Clinical Significance", "content": "BCG vaccination after infancy has a substantial effect on tuberculin skin test (TST) reactivity.\u00a0 BCG trial in the United States showed that individuals who received BCG after infancy had tuberculin skin test reactions \u226510 mm up to 55 years post-immunization. [29]", "contents": "Bacillus Calmette Guerin -- Clinical Significance. BCG vaccination after infancy has a substantial effect on tuberculin skin test (TST) reactivity.\u00a0 BCG trial in the United States showed that individuals who received BCG after infancy had tuberculin skin test reactions \u226510 mm up to 55 years post-immunization. [29]"}
{"id": "article-18172_14", "title": "Bacillus Calmette Guerin -- Clinical Significance", "content": "Prior BCG vaccination should not affect the interpretation of TST results in individuals vaccinated at birth more than ten years earlier given that most individuals who receive the BCG vaccine come from areas where there is a high incidence of TB. \u00a0Interferon-gamma release assays (IGRAs) should be used to interpret positive TSTs in persons with a history of BCG immunization since this test is not affected by BCG administration.\u00a0 In individuals exposed to serial tuberculin testing, previous BCG vaccination may be increased, leading to a positive skin test in an individual with a prior negative skin test.\u00a0Greater than 50 percent of patients that received intravesical BCG for bladder cancer have been reported to result in conversion to a positive tuberculin skin test.\u00a0This exposure to intravesical BCG should not result in a positive IGRA result. [30] [31]", "contents": "Bacillus Calmette Guerin -- Clinical Significance. Prior BCG vaccination should not affect the interpretation of TST results in individuals vaccinated at birth more than ten years earlier given that most individuals who receive the BCG vaccine come from areas where there is a high incidence of TB. \u00a0Interferon-gamma release assays (IGRAs) should be used to interpret positive TSTs in persons with a history of BCG immunization since this test is not affected by BCG administration.\u00a0 In individuals exposed to serial tuberculin testing, previous BCG vaccination may be increased, leading to a positive skin test in an individual with a prior negative skin test.\u00a0Greater than 50 percent of patients that received intravesical BCG for bladder cancer have been reported to result in conversion to a positive tuberculin skin test.\u00a0This exposure to intravesical BCG should not result in a positive IGRA result. [30] [31]"}
{"id": "article-18172_15", "title": "Bacillus Calmette Guerin -- Clinical Significance", "content": "The rationale for the development of a booster vaccine is due to decreasing immunity about 15-20 years after the initial immunization at infancy [32] . However, studies done in Brazil and Malawi have shown that a booster dose of the BCG vaccine is not very effective against TB disease [33] [34] [35] . BCG vaccine may offer protection against infections due to nontuberculous mycobacteria. [36]", "contents": "Bacillus Calmette Guerin -- Clinical Significance. The rationale for the development of a booster vaccine is due to decreasing immunity about 15-20 years after the initial immunization at infancy [32] . However, studies done in Brazil and Malawi have shown that a booster dose of the BCG vaccine is not very effective against TB disease [33] [34] [35] . BCG vaccine may offer protection against infections due to nontuberculous mycobacteria. [36]"}
{"id": "article-18172_16", "title": "Bacillus Calmette Guerin -- Clinical Significance", "content": "Studies have shown that the BCG vaccine decreases the risk of disease due to Mycobacterium leprae by 50 to 80 percent and this effect is increased with booster doses of BCG. [34] [37] Prior studies had shown that the vaccine is also 50 percent effective in preventing Buruli ulcer disease due to M. ulcerans, but a more recent retrospective study failed to show evidence that BCG protected against Buruli ulcer disease. [38]", "contents": "Bacillus Calmette Guerin -- Clinical Significance. Studies have shown that the BCG vaccine decreases the risk of disease due to Mycobacterium leprae by 50 to 80 percent and this effect is increased with booster doses of BCG. [34] [37] Prior studies had shown that the vaccine is also 50 percent effective in preventing Buruli ulcer disease due to M. ulcerans, but a more recent retrospective study failed to show evidence that BCG protected against Buruli ulcer disease. [38]"}
{"id": "article-18172_17", "title": "Bacillus Calmette Guerin -- Clinical Significance", "content": "BCG vaccination also protects against childhood lymphadenitis due to M. avium complex [39] has been an increase in childhood adenitis due to non-tuberculous mycobacteria since the cessation of childhood BCG immunization. [40] [41]", "contents": "Bacillus Calmette Guerin -- Clinical Significance. BCG vaccination also protects against childhood lymphadenitis due to M. avium complex [39] has been an increase in childhood adenitis due to non-tuberculous mycobacteria since the cessation of childhood BCG immunization. [40] [41]"}
{"id": "article-18172_18", "title": "Bacillus Calmette Guerin -- Clinical Significance", "content": "Tuberculin skin test (TST)\u00a0reaction of 3 to 19 mm in size is expected in most individuals that received BCG immunization two to three months after vaccination.\u00a0 In a study of 5952 individuals who had BCG vaccination and subsequently underwent tuberculin skin testing 10 to 25 years later, only 8 percent had positive skin test results. [31]", "contents": "Bacillus Calmette Guerin -- Clinical Significance. Tuberculin skin test (TST)\u00a0reaction of 3 to 19 mm in size is expected in most individuals that received BCG immunization two to three months after vaccination.\u00a0 In a study of 5952 individuals who had BCG vaccination and subsequently underwent tuberculin skin testing 10 to 25 years later, only 8 percent had positive skin test results. [31]"}
{"id": "article-18172_19", "title": "Bacillus Calmette Guerin -- Enhancing Healthcare Team Outcomes", "content": "BCG vaccination policy is determined by the regional prevalence of tuberculosis infection. Routine neonatal vaccination is recommended by the WHO in countries with moderate to the severe incidence of tuberculosis.\u00a0Conversion of tuberculin skin test should not be used to determine the efficacy of the BCG vaccine among\u00a0recipients. [34] [35] [42]", "contents": "Bacillus Calmette Guerin -- Enhancing Healthcare Team Outcomes. BCG vaccination policy is determined by the regional prevalence of tuberculosis infection. Routine neonatal vaccination is recommended by the WHO in countries with moderate to the severe incidence of tuberculosis.\u00a0Conversion of tuberculin skin test should not be used to determine the efficacy of the BCG vaccine among\u00a0recipients. [34] [35] [42]"}
{"id": "article-18172_20", "title": "Bacillus Calmette Guerin -- Enhancing Healthcare Team Outcomes", "content": "Routine BCG vaccination is not generally recommended in the United States due to a low incidence of tuberculosis infection and also due to interference of immunization with the PPD test. BCG vaccination is not recommended for health care workers in low-risk areas. Vaccination is also contraindicated in immunosuppressed patients.", "contents": "Bacillus Calmette Guerin -- Enhancing Healthcare Team Outcomes. Routine BCG vaccination is not generally recommended in the United States due to a low incidence of tuberculosis infection and also due to interference of immunization with the PPD test. BCG vaccination is not recommended for health care workers in low-risk areas. Vaccination is also contraindicated in immunosuppressed patients."}
{"id": "article-18172_21", "title": "Bacillus Calmette Guerin -- Enhancing Healthcare Team Outcomes", "content": "BCG vaccination may be considered in situations where a high percentage of patients are infected with TB strains that are resistant to isoniazid and rifampin. [42] Vaccination can also be found in\u00a0cases\u00a0where the implementation of general infection precautions has failed and when transmission of multi-drug resistant strain of Mycobacterium tuberculosis is likely. [42] Nurses practitioners, physician\u00a0assistants, and physicians\u00a0that administer BCG should work together in an interprofessional team to assure the safe and effective administration, follow-up, and education of the patient. [Level 5]", "contents": "Bacillus Calmette Guerin -- Enhancing Healthcare Team Outcomes. BCG vaccination may be considered in situations where a high percentage of patients are infected with TB strains that are resistant to isoniazid and rifampin. [42] Vaccination can also be found in\u00a0cases\u00a0where the implementation of general infection precautions has failed and when transmission of multi-drug resistant strain of Mycobacterium tuberculosis is likely. [42] Nurses practitioners, physician\u00a0assistants, and physicians\u00a0that administer BCG should work together in an interprofessional team to assure the safe and effective administration, follow-up, and education of the patient. [Level 5]"}
{"id": "article-18172_22", "title": "Bacillus Calmette Guerin -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Bacillus Calmette Guerin -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}